This CME/CE program will provide an evidence-based review of biosimilar therapeutics for patients with relapsing multiple sclerosis, with a focus on approval standards, clinical evidence, and practical implications for neurologists as well as for the broader healthcare team. The program will distinguish between generic and biosimilar medications, emphasizing the differences in molecule complexity, regulatory pathways, required clinical evidence, and immunogenicity testing. Neuroinflammatory disease expert faculty Dr. Benjamin M. Greenberg, will review real-world concerns associated with certain generic MS therapies, as well as with the growing safety and efficacy data supporting biosimilars across the neurology, rheumatology, oncology, and gastroenterology treatment landscapes. Dr. Greenberg will examine biosimilar natalizumab, and rituximab, as well as emerging anti-CD20 biosimilar data, including clinical trial results, switching evidence, and real-world patient experiences. To conclude, the program will address patient counseling strategies, the nocebo effect, access and cost considerations for biosimilars, and the important role of shared decision-making in biosimilar adoption to improve outcomes and quality of life for patients with MS.
MS specialists, other neurologists, and other healthcare professionals involved in the management of patients with multiple sclerosis
AcademicCME
Review strategies to assess individualized patient characteristics and disease prognosis to determine the role of biosimilar therapeutics in treatment planning
Develop treatment plans to delay disability and progression in patients with MS
Review and analyze clinical trial data for biosimilar therapeutics to manage patients with MS
Biosimilars in Medicine
– Generic Versus Biosimilars
– Process for Biosimilar Approval
Clinical Impact of Biosimilars in Medicine and Neurology
– Experience with Biosimilars in Oncology and Rheumatology
– Biosimilars Used in Neurology: Rituximab, Infliximab, Natalizumab Data
Strategies for Patient Prescribing
– Patient Education
– Patient Monitoring
– Lab Testing
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty
have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Benjamin M. Greenberg, MD, MHS | Consultant/Advisor: Alexion Pharmaceuticals; Amgen; EMD Serono; Genentech, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Roche AG; Sandoz; Sanofi; TG Therapeutics, Inc. |
Timothy Hayes, MD, PhD; Joseph Feick, PharmD; Kim Cheramie, PhD, MSN, RN, NPDA-BC, Nicole McMenamin and Chelsey Simonds hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.
AcademicCME designates this enduring material for a maximum of 0.75 CNE Contact Hours, including 0.75 Pharmacotherapeutic Contact Hours (Provider #P0491).
AcademicCME designates this continuing education activity for 0.75 CPE Contact Hours (0.075 CEUs) of Continuing Pharmacy Education Credit (UAN # JA4008190-0000-26-015-H01-P).
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an independent educational grant from Sandoz.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Sandoz do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
